Jump to main content
Jump to site search

Issue 9, 2017
Previous Article Next Article

Structure-optimized dihydropyranoindole derivative GIBH-LRA002 potentially reactivated viral latency in primary CD4+ T lymphocytes of chronic HIV-1 patients

Author affiliations

Abstract

Based on structure modification and a high-throughput Jurkat-Lat cell screening model, we found that GIBH-LRA002, ethyl-2-amino-3-cyano-9-methyl-4-(trifluoromethyl)-4,9-dihydropyrano[2,3-b]indole-4-carboxylate, effectively reactivated the latent proviruses in a Jurkat-Lat cell line and primary CD4+ T cells from both chronic SIV-infected rhesus macaques and HIV-1 patients but without inducing systemic activation, making this compound attractive for potentially treating HIV-1 infection.

Graphical abstract: Structure-optimized dihydropyranoindole derivative GIBH-LRA002 potentially reactivated viral latency in primary CD4+ T lymphocytes of chronic HIV-1 patients

Back to tab navigation

Supplementary files

Publication details

The article was received on 28 Jun 2017, accepted on 21 Jul 2017 and first published on 25 Jul 2017


Article type: Research Article
DOI: 10.1039/C7MD00327G
Citation: Med. Chem. Commun., 2017,8, 1806-1809
  •   Request permissions

    Structure-optimized dihydropyranoindole derivative GIBH-LRA002 potentially reactivated viral latency in primary CD4+ T lymphocytes of chronic HIV-1 patients

    Q. Yang, Y. Ding, F. Feng, E. Pan, X. Fan, X. Ma, L. Chen, J. Zhao and C. Sun, Med. Chem. Commun., 2017, 8, 1806
    DOI: 10.1039/C7MD00327G

Search articles by author

Spotlight

Advertisements